TCGA-OR-A5JG-01
Adrenocortical Carcinoma · Adrenocortical Carcinoma · Adrenocortical Carcinoma, Usual Type
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Adrenocortical Carcinoma
- cancer_type_detailed
- Adrenocortical Carcinoma
- subtype
- Adrenocortical Carcinoma, Usual Type
- cancer_type
- Adrenocortical Carcinoma
- cancer_type_detailed
- Adrenocortical Carcinoma
- subtype
- Adrenocortical Carcinoma, Usual Type
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.573
- MYC_TARGETS_V1+0.484
- E2F_TARGETS+0.354
- UNFOLDED_PROTEIN_RESPONSE+0.339
- OXIDATIVE_PHOSPHORYLATION+0.324
- PANCREAS_BETA_CELLS+0.285
- G2M_CHECKPOINT+0.270
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.236
- DNA_REPAIR+0.221
- PROTEIN_SECRETION+0.169
Top 10 suppressed
- CHOLESTEROL_HOMEOSTASIS-0.418
- WNT_BETA_CATENIN_SIGNALING-0.361
- APICAL_SURFACE-0.346
- MYOGENESIS-0.287
- INTERFERON_ALPHA_RESPONSE-0.264
- APOPTOSIS-0.261
- TGF_BETA_SIGNALING-0.260
- NOTCH_SIGNALING-0.256
- INFLAMMATORY_RESPONSE-0.244
- UV_RESPONSE_DN-0.229
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 4fd42f6e-b04a-4726-b35f-a19d17a6e7bb | — | — | 0.846 |
| 2 | TCGA-66-2754-01A-01R-0980-07 | — | cohortA3 | 0.843 |
| 3 | debb199a-24be-4e87-84ea-2df67673457a | — | — | 0.841 |
| 4 | TCGA-AN-A03Y-01A-21R-A00Z-07 | — | B | 0.821 |
| 5 | BS_YBJBSRHV | Embryonal tumors | — | 0.819 |
| 6 | TCGA-4Z-AA87-01A-11R-A39I-07 | — | — | 0.810 |
| 7 | TCGA-HD-A634-01A-11R-A28V-07 | — | — | 0.809 |
| 8 | BS_JTMXAMB7 | medulloblastoma | — | 0.804 |
| 9 | 2d8cab40-0dda-4d6d-a9ba-83a82a7e1c15 | — | — | 0.803 |
| 10 | C3N-02089 | — | cohortA4 | 0.801 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.573 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.484 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.354 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.339 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.324 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.285 | Cobimetinib | — uncovered |
| G2M_CHECKPOINT | 0.270 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.236 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.221 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.169 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.154 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.092 | Idelalisib | — uncovered |
| PEROXISOME | 0.056 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.053 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.050 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.023 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.019 | Inavolisib | — uncovered |